<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/027565E4-50E9-45A7-B48D-D81688C836CF"><gtr:id>027565E4-50E9-45A7-B48D-D81688C836CF</gtr:id><gtr:name>WaVe Biosciences</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/8F41604A-4001-4CBF-BE9A-EE225EEF113F"><gtr:id>8F41604A-4001-4CBF-BE9A-EE225EEF113F</gtr:id><gtr:name>Isis Pharmaceuticals</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:department>Molecular Medicine</gtr:department><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/027565E4-50E9-45A7-B48D-D81688C836CF"><gtr:id>027565E4-50E9-45A7-B48D-D81688C836CF</gtr:id><gtr:name>WaVe Biosciences</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/8F41604A-4001-4CBF-BE9A-EE225EEF113F"><gtr:id>8F41604A-4001-4CBF-BE9A-EE225EEF113F</gtr:id><gtr:name>Isis Pharmaceuticals</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/ACD6437C-C203-4D72-B0AF-9A502AB5C3BF"><gtr:id>ACD6437C-C203-4D72-B0AF-9A502AB5C3BF</gtr:id><gtr:firstName>William</gtr:firstName><gtr:otherNames>Henry</gtr:otherNames><gtr:surname>McLean</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1310207A-56D8-481F-980E-4F4C60A5300F"><gtr:id>1310207A-56D8-481F-980E-4F4C60A5300F</gtr:id><gtr:firstName>Frances</gtr:firstName><gtr:otherNames>Jane</gtr:otherNames><gtr:surname>Smith</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0802780"><gtr:id>FEC83CBE-A34F-4A0A-8F55-717EC55F53EB</gtr:id><gtr:title>siRNA therapy in dominant skin and eye disorders</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0802780</gtr:grantReference><gtr:abstractText>Incurable genetic diseases represent a major cost to the NHS, requiring specialist care costing billions per annum. RNA interference is a new Nobel prize winning technology that is suitable for treatment of a large number of genetic disorders but a major hurdle to applying this clinically is the the problem of delivery of these therapy molecules, that are slightly larger than conventional drugs, into the target tissues and organs. This programme grant focuses on a group of painful, debilitating genetic skin diseases and a related corneal eye disease, where the target tissues are very small and very accessible. The programme brings together leading researchers who uncovered the genes causing these disorders, with experts in developing new methods to deliver molecules into skin or cornea. State-of-the-art model systems will be developed to validate delivery of these new formulations into the skin and the cornea, setting the scene for taking this new therapy method into the clinic.</gtr:abstractText><gtr:technicalSummary>Despite the progress in identification of genes causing human disease, development of therapies tailored to these genetic defects has been disappointingly slow. RNAi represents a promising new means of silencing genes or mutant alleles, particularly in dominant conditions, however, a major hurdle is delivery of these agents in vivo. The palm/sole epidermis and the ocular surface epithelium are two very accessible target tissues of limited size, with obvious advantages for development of RNAi therapy. Here, we will perform identification and lead optimisation of gene-specific and mutation-specific siRNA inhibitors for keratin disorders of palmoplantar epidermis and of cornea. We will systematically compare the efficacy, specificity and stability of alternative methods of gene-specific and allele-specific silencing including morpholino oligonucleotides, locked nucleic acids (LNA) and peptide nucleic acids (PNA), relative to optimised lead siRNA inhibitors. We will develop a novel multi-target reporter gene mouse where a bioluminescence signal is targeted to footpad epidermis as a preclinical model for epidermal keratin disorders. This will be complemented by a phenotypic model of footpad hyperkeratosis. We will develop an analogous multi-target bioluminescent reporter gene mouse and a phenotypic corneal dystrophy mouse as preclinical models of a corneal keratin disorder. We will develop and optimise non-invasive methods for siRNA delivery into the skin and into the corneal epithelium, using the appropriate animal models generated. Using two different, complementary target tissues increases the chances of successful translation of this technology into human application. Solving the siRNA delivery problem opens up this technology for treatment of a wide range of incurable genetic diseases that collectively amount to a massive healthcare burden.</gtr:technicalSummary><gtr:fund><gtr:end>2015-02-17</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-02-18</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1426708</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>The Roslin Institute</gtr:department><gtr:description>Roslin</gtr:description><gtr:id>2ED0CDF4-3192-4EAE-9E3F-02789C34A538</gtr:id><gtr:impact>This collaboration is helping us optimise an ex vivo skin culture system. No final outcome yet.</gtr:impact><gtr:partnerContribution>Provision of discarded pig skin following ova harvesting.</gtr:partnerContribution><gtr:piContribution>Developing systems for ex vivo culture of skin.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Isis Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>ISIS Pharmaceuticals</gtr:description><gtr:id>EF5AC03F-7EF1-4991-A491-88F9F31E73A6</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:partnerContribution>None as yet but we anticipate that we will receive antisense molecules developed by ISIS in 2015 to test in our model systems under development.</gtr:partnerContribution><gtr:piContribution>We are developing assay systems to test therapeutic antisense oligonucleotides for silencing the mouse and human KRT6A gene. ISIS will subsequently develop antisense molecules to test in our systems and hopefully progress these towards clinical application in the future.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>WaVe Biosciences</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>WaVe</gtr:description><gtr:id>B0AA0D95-3543-4F91-9A20-9EFAF7291FEB</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:partnerContribution>None as yet but we anticipate obtaining &amp;quot;stereopure&amp;quot; oligonucleotides for testing in 2015.</gtr:partnerContribution><gtr:piContribution>We established an informal collaboration with WaVe Biosciences in 2014 to test their proprietary &amp;quot;stereopure&amp;quot; antisense oligonucleotides using in vitro and in vivo model systems we have available.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>PC Steering Group</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B480ECD6-598F-46FB-B931-CABB3F9210AF</gtr:id><gtr:impact>Steering group for international pachyonychia congenita research consortium planning clinical trials and future research.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Consultant Geneticist on Channel 4's &quot;Embarrassing Bodies&quot;</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>58DE6568-83C3-483B-A795-49A46E320795</gtr:id><gtr:impact>Consultant on Channel 4's &amp;quot;Embarrassing Bodies&amp;quot; in relation to an undiagnosed patient with pachyonychia congenita. Following this mass-media appearance, more than 50 new undiagnosed families with pachyonychia congenita or related conditions contacted the research group and were given genetic testing and patient support. The programme has been repeated in the UK and other nations worldwide, and each time, further undiagnosed families have come forth and been given genetic testing, contact with patient groups and other support. Many famililes contacted in this way have attended patient support meetings organised by the group.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Scottish EBS Patient Support Meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>85D45052-39D8-456C-944B-9E0D8A0D42A7</gtr:id><gtr:impact>About 100 patients and family members with the inherited skin blistering disease epidermolysis bullosa simplex (EBS) attended a 1-day meeting to learn about the molecular basis of their disease and progress being made in therapy development.

The success of this meeting led to organisation of bigger meeting in the south of England (May 2012) and north of England (Nov 2012), with help from the EB charity, DEBRA.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release, Wellcome Trust Strategic Award to Dundee Dermatology and Genetic Medicine</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>44D2D31A-3A24-4188-B377-84F08ED44A07</gtr:id><gtr:impact>Media interviews about the Wellcome Trust's major funding boost for dermatology research at the University of Dundee
e.g. http://www.bbc.co.uk/news/uk-scotland-tayside-central-18883942</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Talk, South West Scotland</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B720A881-D90E-416C-AB10-8A4A6B687148</gtr:id><gtr:impact>By direct invitation, a 45 min presentation was given to about 100 members of the public involved in fund-raising for skin disease charities, particularly relating to the filaggrin gene in ichthyosis, common dry skin and eczema/allergy, as well as outlining our efforts to develop therapies based on this gene. Lengthy discussion followed - about 15 min formal and 2 hours informal.

Small financial donation to the lab was received from this group.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK (South) Epidermolysis bullosa simplex patient support meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>EAD683D8-CFCD-4766-9481-114C57E5F0E4</gtr:id><gtr:impact>About 100 patients with epidermolysis bullosa simplex (EBS) and their carers/families attended a 1 day meeting in Reading, co-organised by the Dundee group and the patient support organisation DEBRA. The purpose of this meeting was to update these individuals on the state of the art in relation to understanding the molecular basis of their disease and importantly, what therapies are in development.

None as yet.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Discovery of a new skin disease gene</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DBAD876E-23E1-4534-9C6D-686A37F62822</gtr:id><gtr:impact>Media interviews following this discovery of a new skin disease gene and the mechanisms through which it operates
e.g. http://www.bbc.co.uk/news/uk-scotland-tayside-central-19928039</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DEBRA Annual Conference, Weybridge, UK</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>058CC16D-B469-444F-9178-7B2B66EB7148</gtr:id><gtr:impact>More than 100 patients with the inherited skin blistering disorder epidermolysis bullosa simplex (EBS) attended 1-day meetings in Weybridge, South of England, and Staffordshire, South of England, to learn about the molecular basis of their disease and hear about progress being made in therapy development.

Owing to the success of this meeting and the preceding one in Scotland, a follow-up meeting was organised to spread this information to patients in the north of England in November 2012. These EBS patient meetings will now be an annual event.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2012,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PC Project European Patient Support Meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1FD36BFE-68E5-4BDF-8515-8DD021034AE2</gtr:id><gtr:impact>About 100 patients and family members affected by the genetic skin disease pachyonychia congenita from all over Europe attended a 2 day meeting organised by this research group. This allowed close interaction of patients, family members, clinicians and scientists. This meeting is run every 2 years by the Dundee group and was hosted in Dundee in 2006, 2008 and in Edinburgh 2010, 2012, 2014.

Very positive feedback received from the patients and other attendees.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2008,2010,2012,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release on discovery of the matted gene in atopic eczema</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>064AF8FA-C72D-4326-A545-922FB2AB19B0</gtr:id><gtr:impact>Local radio interview and newspaper coverage on discovery of the matted mouse gene in atopic eczema.
Press release, 6th Nov 2013: http://www.dundee.ac.uk/pressreleases/2013/november13/eczema.htm</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DEBRA UK research leadership visit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>79978A13-EC39-4705-A518-6A7165428479</gtr:id><gtr:impact>Visits from DEBRA UK Research Managers and lead fundraisers to laboratories, with updates on current research and future planning.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PC Project France Patient support meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7B17FDC1-4EEF-4721-8329-B0DF3362C206</gtr:id><gtr:impact>About 50 French patients and family members affected by the skin disease pachyonychia congenita attended a 2 day French language workshop organised by members of the Dundee group. This will be a biannual meeting from now on, with the next one scheduled for 2012.

Very positive feedback obtained from the families. This is to be a bi-annual event, next meeting 2016.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010,2012,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Arts-Science Public Lecture</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>3CB11D28-E27F-424D-BC36-9CB969BF4B7C</gtr:id><gtr:impact>A talk was given by an artist who uses skin disease as subject matter, to increase awareness of skin conditions. This was followed by a lay talk on skin disease research, followed by a panel discussion with both the artist and scientist, sharing and exchanging their specific views on this field and looking for ways in which each others perspectives would stimulate further art and science work in skin. This was followed by a lively question and answer session with the general public audience. Our work on the cornea was also briefly presented.

None to date but the artist is interested to participate in future patient meetings hosted by the Dundee group, to gain more insights into skin conditions. The aim is to work together with the Dundee science group in future to continue to raise awareness of neglected skin disease through art works.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release regarding Buchanan Medal</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F2360482-B5C0-4194-8FD5-5B27FFCD3E76</gtr:id><gtr:impact>Press release on Buchannan Medal of the Royal Society, local and national press coverage
http://www.dundee.ac.uk/news/2015/professor-irwin-mclean-awarded-buchanan-medal-by-royal-society.php</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.dundee.ac.uk/news/2015/professor-irwin-mclean-awarded-buchanan-medal-by-royal-society.php</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pachyonychia congenita patient support, Hefei, China</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>54880F5F-7F93-4F8E-8BF9-A1AAEF51B078</gtr:id><gtr:impact>About 20 patients with pachyonychia congenita plus their attendant family members, clinicians and scientists, all from mainland China, attended the first patient support meeting for this disease in the Far East.

Positive feedbak received from Chinese patients, many of whom had never had a firm diagnosis or any real understanding of their disease. A number of patients were given genetic diagnosis as a result of this meeting and some misdiagnosed cases correctly reassigned.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PC Project European Patient Support Meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>565BA0DA-59E1-4A69-9193-46F7B0C5684A</gtr:id><gtr:impact>More than 100 patients and family members affected by the skin disease pachyonychia congenita attended a 2 day meeting in Edinburgh organised by the Dundee research group.

Very positive feedback received from patients and their families. This is now a biannual event, with the next date set for Oct 2014.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2006,2008,2010,2012,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Undergraduate Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>365AC705-05CD-4D36-97E6-2737C7BD1E79</gtr:id><gtr:impact>Undergraduate Open Day, School of Life Sciences</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release about discovery of 10 eczema genes</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>99B48B4D-09AC-4121-8615-BC557ACBF9B5</gtr:id><gtr:impact>Press release on identification of 10 new eczema genes; local and national press coverage; local radio interviews; international web coverage
www.dundee.ac.uk/research/main/news/20151020115352/1006.html</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.dundee.ac.uk/research/main/news/20151020115352/1006.html</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PC Project America Patient support meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>994E1077-52DC-447A-8125-4EC6B4D0281C</gtr:id><gtr:impact>About 100 patients and family members affected by the skin disease pachyonychia congenita attended a 2 day workshop in North America, co-organised by members of the Dundee research group. These meetings are run every 2 years in the USA or Canada for the benefit of patients from the Americas.

Very positive feedback received from patients.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007,2009,2011,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release about election to The Royal Society</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D8390039-9103-49E3-8EDD-0207CFE3D836</gtr:id><gtr:impact>Press release about election to The Royal Society:
http://www.dundee.ac.uk/news/2014/professor-irwin-mclean-elected-to-royal-society.php
Several press articles and local radio coverage</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.dundee.ac.uk/news/2014/professor-irwin-mclean-elected-to-royal-society.php</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Lecture (British Association for the Advancement of Science)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>3F10B26F-A19A-4241-B27E-BEA7938A1FB2</gtr:id><gtr:impact>&amp;quot;Are you thick skinned enough? Dermatology Discoveries in Dundee&amp;quot;. Audience of about 60 people, all from the Tayside region general public. 60 min lecture plus 30 min discussion.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK (North) Epidermolysis bullosa simplex patient support meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0AC6A3E1-FA0E-47C9-B176-E547BC3DECD3</gtr:id><gtr:impact>More than 100 patients with the inherited skin blistering disorder epidermolysis bullosa simplex (EBS) attended 1-day meetings in Manchester, and in Dundee to learn about the molecular basis of their disease and hear about progress being made in therapy development.

These EBS patient meetings will now be an annual event, with 3 being held (Scotland, North of England, South of England) to cover the UK and allow patients to travel to the nearest venue.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2012,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6BD743A9-ECD4-4FAE-A47C-713EB4050F28</gtr:id><gtr:impact>65 people attended the public lecture.

Invited to do a follow-up lecture in 2014</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.cafesciencedundee.co.uk/?p=1235</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Lecture, Comber Rotary Club, County Down, Northern Ireland.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6F987C43-6DD0-4D39-BB4C-D0823A47C01D</gtr:id><gtr:impact>Public talk hosted by a Rotary Club. &amp;quot;Studying inherited skin disease through thick and thin&amp;quot;. Audience of about 30-40 Rotarians and interested public. 30 min lecture plus 15 min discussion.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>126206</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Pachyonychia Conenita Project (PC Project)</gtr:fundingOrg><gtr:id>178A6F56-A5D6-4880-A4F9-4BA9F3D56B62</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>111995</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Pachyonychia Conenita Project (PC Project)</gtr:fundingOrg><gtr:id>EA1BA82F-7050-4C01-B148-6F84D09D4E03</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>82258</gtr:amountPounds><gtr:country>Austria, Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Fellowship</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>Dystrophic Epidermolysis Bullosa Research Association (DEBRA)</gtr:fundingOrg><gtr:id>45D9D67C-9471-4858-A95E-81A30583E901</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>Unknown</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Industrial collaboration</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Wave Life Sciences</gtr:fundingOrg><gtr:id>8C9EE440-D894-4847-AA79-D43151A1F073</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>299558</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Horizon 2020</gtr:department><gtr:description>Marie Curie Fellowship</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>547B422D-0482-43DC-B826-C7BFCDB030CC</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>169773</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Fight for Sight</gtr:fundingOrg><gtr:fundingRef>1450/1</gtr:fundingRef><gtr:id>C392C16F-01FF-46F8-ACA3-85312C757DA4</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>38500</gtr:amountPounds><gtr:country>Austria, Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Dystrophic Epidermolysis Bullosa Research Association (DEBRA)</gtr:fundingOrg><gtr:id>B7047684-FBB8-42F0-8CF0-4860C2E70237</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5869875</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Strategic Award</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>098439/Z/12/Z</gtr:fundingRef><gtr:id>B97B4BB9-9A3D-4896-9C6A-11818D34BE7F</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>81000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>British Skin Foundation</gtr:fundingOrg><gtr:id>ED59D984-33ED-4986-A432-28D00BEC74C2</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>548800</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>New Investigator Award</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>MRC-UK</gtr:fundingOrg><gtr:id>8935AA35-6D58-44F3-B1A5-AF6F53BB6014</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2014-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>European Dermatology Forum</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>B0937C5A-EB64-42B5-BFCA-8A97F7C15659</gtr:id><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Knock-in mouse expressing luciferase under the control of the murine Krt9 gene. Carries multiple therapy target sequences.</gtr:description><gtr:id>6E6C7D7A-D6DA-46D7-BD69-62869898A87A</gtr:id><gtr:impact>Publication planned 2015.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>K9-luciferase reporter gene mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Knock-in mouse expressing human KRT12 gene carrying a dominant-negative mutation under control of the murine Krt12 gene.</gtr:description><gtr:id>06788871-528A-489C-8060-764E0C57B385</gtr:id><gtr:impact>Manuscript at advanced stage, submission planned Q4 of 2014.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>K12 humanized knock-in mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Knockout mouse for the palm/sole specific keratin gene Krt9 encoding the K9 protein.</gtr:description><gtr:id>99EFBDDA-9F7F-48E0-8A08-D7F88882943C</gtr:id><gtr:impact>Paper published in 2013 (on-line) and 2014 (print):

Fu DJ, Thomson C, Lunny DP, Dopping-Hepenstal PJ, McGrath JA, Smith FJD, McLean WHI and Leslie Pedrioli DM (2014) Keratin 9 is Required for the Structural Integrity and Terminal Differentiation of Palmoplantar Epidermis. J Invest Dermatol 134:754-763 [Epub ahead of print Aug 20, 2013] (PubMed ID: 23962810)</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>K9 knockout mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Knock-in mouse carrying a dominant-negative mutation in the human KRT9 gene.</gtr:description><gtr:id>7E4970A9-4CB3-435C-BF82-CED3DD1F4914</gtr:id><gtr:impact>Publication planned 2015.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>K9 humanized knock-in mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Expresses luciferase reporter gene under the control of the murine Krt12 gene. Carries multiple human therapy target sequences.</gtr:description><gtr:id>CD20F739-BA0A-4656-AAB5-917B8E1E03DD</gtr:id><gtr:impact>Manuscript at advanced stage, for submission Q4 of 2014.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>K12-luciferase knock-in mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A3A06E26-5D36-4F3B-938E-A3CA43E868C6"><gtr:id>A3A06E26-5D36-4F3B-938E-A3CA43E868C6</gtr:id><gtr:title>Heterozygous mutations in AAGAB cause type 1 punctate palmoplantar keratoderma with evidence for increased growth factor signaling.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3684e428541d257e812fb12f6952ed2b"><gtr:id>3684e428541d257e812fb12f6952ed2b</gtr:id><gtr:otherNames>P?hler E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9490A6DE-316A-4728-B2AE-D82B54E33F19"><gtr:id>9490A6DE-316A-4728-B2AE-D82B54E33F19</gtr:id><gtr:title>Calpain 12 Function Revealed through the Study of an Atypical Case of Autosomal Recessive Congenital Ichthyosis.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fe2b75ed82061ccc3adde5a13a34d81f"><gtr:id>fe2b75ed82061ccc3adde5a13a34d81f</gtr:id><gtr:otherNames>Bochner R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BD4562C6-EB32-4036-B6F1-BD6640B4EECC"><gtr:id>BD4562C6-EB32-4036-B6F1-BD6640B4EECC</gtr:id><gtr:title>Novel molecular therapies for heritable skin disorders.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/68e09d03badf2c6a33c71d30993b5c56"><gtr:id>68e09d03badf2c6a33c71d30993b5c56</gtr:id><gtr:otherNames>Uitto J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/833F7FE6-BB3C-4B25-9F61-16F8464A2AF0"><gtr:id>833F7FE6-BB3C-4B25-9F61-16F8464A2AF0</gtr:id><gtr:title>Toward a treatment for pachyonychia congenita: report on the 7th Annual International Pachyonychia Congenita Consortium meeting.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/08106e20b29c075afbbad3226ae231ed"><gtr:id>08106e20b29c075afbbad3226ae231ed</gtr:id><gtr:otherNames>Kaspar RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EBBECAB6-7513-474E-A012-1BAE3133D9AD"><gtr:id>EBBECAB6-7513-474E-A012-1BAE3133D9AD</gtr:id><gtr:title>Single-nucleotide-specific siRNA targeting in a dominant-negative skin model.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bb2b3892d790bb4dcf1068f75965dad2"><gtr:id>bb2b3892d790bb4dcf1068f75965dad2</gtr:id><gtr:otherNames>Hickerson RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BB7A4390-889D-4AFA-8FEC-B21E3CEDD5B0"><gtr:id>BB7A4390-889D-4AFA-8FEC-B21E3CEDD5B0</gtr:id><gtr:title>Development of quantitative molecular clinical end points for siRNA clinical trials.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bb2b3892d790bb4dcf1068f75965dad2"><gtr:id>bb2b3892d790bb4dcf1068f75965dad2</gtr:id><gtr:otherNames>Hickerson RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C2A95538-8998-43EE-977E-C6372E6A5748"><gtr:id>C2A95538-8998-43EE-977E-C6372E6A5748</gtr:id><gtr:title>Keratin 12 missense mutation induces the unfolded protein response and apoptosis in Meesmann epithelial corneal dystrophy.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9c89a5fb166c140e6fb30bd0d146c474"><gtr:id>9c89a5fb166c140e6fb30bd0d146c474</gtr:id><gtr:otherNames>Allen EH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/26346492-75D8-46B7-9AFC-5F5AECD65FAC"><gtr:id>26346492-75D8-46B7-9AFC-5F5AECD65FAC</gtr:id><gtr:title>Generation and characterisation of keratin 7 (K7) knockout mice.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/55b03925a89ecafca13d607e205db131"><gtr:id>55b03925a89ecafca13d607e205db131</gtr:id><gtr:otherNames>Sandilands A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/513D9E5F-2082-403D-AC41-CC24858EE365"><gtr:id>513D9E5F-2082-403D-AC41-CC24858EE365</gtr:id><gtr:title>First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/33c495952b4fc5fe6774d1b49df82ab2"><gtr:id>33c495952b4fc5fe6774d1b49df82ab2</gtr:id><gtr:otherNames>Leachman SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/213DC049-CF58-42A2-A950-1A1D4337727D"><gtr:id>213DC049-CF58-42A2-A950-1A1D4337727D</gtr:id><gtr:title>Generic and personalized RNAi-based therapeutics for a dominant-negative epidermal fragility disorder.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b694ac73ae81bc1d9795abb4ece7cd7"><gtr:id>9b694ac73ae81bc1d9795abb4ece7cd7</gtr:id><gtr:otherNames>Leslie Pedrioli DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/182DEF84-C2CC-4C62-A50C-0D43FCC4412A"><gtr:id>182DEF84-C2CC-4C62-A50C-0D43FCC4412A</gtr:id><gtr:title>siRNA silencing of the mutant keratin 12 allele in corneal limbal epithelial cells grown from patients with Meesmann's epithelial corneal dystrophy.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6f942453d6b751e05bcbf8b025afdc00"><gtr:id>6f942453d6b751e05bcbf8b025afdc00</gtr:id><gtr:otherNames>Courtney DG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8DBF63C2-FDC9-4E74-AE3D-B08680880FDB"><gtr:id>8DBF63C2-FDC9-4E74-AE3D-B08680880FDB</gtr:id><gtr:title>A large mutational study in pachyonychia congenita.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ee30dd370782ce25fab3dc90f4cebcf9"><gtr:id>ee30dd370782ce25fab3dc90f4cebcf9</gtr:id><gtr:otherNames>Wilson NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E55E574E-79EF-479B-887F-7339F09ED33A"><gtr:id>E55E574E-79EF-479B-887F-7339F09ED33A</gtr:id><gtr:title>Mutations in POGLUT1 in Galli-Galli/Dowling-Degos disease.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ee30dd370782ce25fab3dc90f4cebcf9"><gtr:id>ee30dd370782ce25fab3dc90f4cebcf9</gtr:id><gtr:otherNames>Wilson NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/61435381-9828-4EC1-BCE0-2ADF890EA571"><gtr:id>61435381-9828-4EC1-BCE0-2ADF890EA571</gtr:id><gtr:title>Keratin 9 is required for the structural integrity and terminal differentiation of the palmoplantar epidermis.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1fab822d9ac530e6c1b15c67b06ed981"><gtr:id>1fab822d9ac530e6c1b15c67b06ed981</gtr:id><gtr:otherNames>Fu DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EB9747B4-0B62-4EA3-B237-F39D8B12F210"><gtr:id>EB9747B4-0B62-4EA3-B237-F39D8B12F210</gtr:id><gtr:title>Keratin disorders: from gene to therapy.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1a06ac4c15fa5ab9d9f15bd95c259659"><gtr:id>1a06ac4c15fa5ab9d9f15bd95c259659</gtr:id><gtr:otherNames>McLean WH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/689DC0B1-1683-4F35-91EB-B75703EE2D32"><gtr:id>689DC0B1-1683-4F35-91EB-B75703EE2D32</gtr:id><gtr:title>Plectin mutations underlie epidermolysis bullosa simplex in 8% of patients.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1cbc80885e79ea401508825ff657df87"><gtr:id>1cbc80885e79ea401508825ff657df87</gtr:id><gtr:otherNames>Bolling MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C25BAD58-F3DA-4C18-9D1A-D80F159658B4"><gtr:id>C25BAD58-F3DA-4C18-9D1A-D80F159658B4</gtr:id><gtr:title>Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f0e930067633bec9e79ed363489cf3a7"><gtr:id>f0e930067633bec9e79ed363489cf3a7</gtr:id><gtr:otherNames>Schmitt J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/957D28B5-B957-4ACF-8A08-1F1E41DB1FB0"><gtr:id>957D28B5-B957-4ACF-8A08-1F1E41DB1FB0</gtr:id><gtr:title>Skin barrier dysfunction measured by transepidermal water loss at 2 days and 2 months predates and predicts atopic dermatitis at 1 year.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/22324572cb1c75685956e986c0c63840"><gtr:id>22324572cb1c75685956e986c0c63840</gtr:id><gtr:otherNames>Kelleher M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AAB12682-69C1-473D-8CF7-5627986B83F6"><gtr:id>AAB12682-69C1-473D-8CF7-5627986B83F6</gtr:id><gtr:title>The phenotypic and molecular genetic features of pachyonychia congenita.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1a06ac4c15fa5ab9d9f15bd95c259659"><gtr:id>1a06ac4c15fa5ab9d9f15bd95c259659</gtr:id><gtr:otherNames>McLean WH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8C8158F8-AEAC-4A02-8C8A-D83A4D86F394"><gtr:id>8C8158F8-AEAC-4A02-8C8A-D83A4D86F394</gtr:id><gtr:title>A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays.</gtr:title><gtr:parentPublicationTitle>PLoS biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ed63a9d2ecf893de047b88ad09ec4f4a"><gtr:id>ed63a9d2ecf893de047b88ad09ec4f4a</gtr:id><gtr:otherNames>McElroy SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1544-9173</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5DC4B72B-0D08-4DC6-A556-86387DC31B9A"><gtr:id>5DC4B72B-0D08-4DC6-A556-86387DC31B9A</gtr:id><gtr:title>Filaggrin breakdown products determine corneocyte conformation in patients with atopic dermatitis.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dc5889dbb3ec7e039ab0cc28012c7ce6"><gtr:id>dc5889dbb3ec7e039ab0cc28012c7ce6</gtr:id><gtr:otherNames>Riethmuller C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E460C993-33A6-4069-A532-030180BCE38C"><gtr:id>E460C993-33A6-4069-A532-030180BCE38C</gtr:id><gtr:title>Development of therapeutic siRNAs for pachyonychia congenita.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b8e6d42aca09807f5cdb5643059d86ab"><gtr:id>b8e6d42aca09807f5cdb5643059d86ab</gtr:id><gtr:otherNames>Smith FJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/43813819-2931-462A-B0E0-5DC14C7FC53D"><gtr:id>43813819-2931-462A-B0E0-5DC14C7FC53D</gtr:id><gtr:title>Report of the 10th Annual International Pachyonychia Congenita Consortium Meeting.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0879dcf7dd41e3a597635d9107aec1ae"><gtr:id>0879dcf7dd41e3a597635d9107aec1ae</gtr:id><gtr:otherNames>van Steensel MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0AFC3DB6-24F9-4690-B671-48E4018D7C1E"><gtr:id>0AFC3DB6-24F9-4690-B671-48E4018D7C1E</gtr:id><gtr:title>In vivo gene silencing following non-invasive siRNA delivery into the skin using a novel topical formulation.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d41aaa72233ee1310e41f89d5608b9b2"><gtr:id>d41aaa72233ee1310e41f89d5608b9b2</gtr:id><gtr:otherNames>Hegde V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5BC4824A-8403-4FAE-A3ED-50AC59BB2D2B"><gtr:id>5BC4824A-8403-4FAE-A3ED-50AC59BB2D2B</gtr:id><gtr:title>Resolution of the plantar hyperkeratosis of pachyonychia congenita during chemotherapy for Ewing sarcoma.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9cfe64b842ee3d7324322468b149221b"><gtr:id>9cfe64b842ee3d7324322468b149221b</gtr:id><gtr:otherNames>Higgins E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9722AC97-EBA4-4E84-B4D6-3FA63A0E8689"><gtr:id>9722AC97-EBA4-4E84-B4D6-3FA63A0E8689</gtr:id><gtr:title>PCQoL: A Quality of Life Assessment Measure for Pachyonychia Congenita.</gtr:title><gtr:parentPublicationTitle>Journal of cutaneous medicine and surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0495674d8deb442af7fae75356037d3e"><gtr:id>0495674d8deb442af7fae75356037d3e</gtr:id><gtr:otherNames>Abbas M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1203-4754</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D50128FE-DC00-43B1-A06C-6965D16FD9CA"><gtr:id>D50128FE-DC00-43B1-A06C-6965D16FD9CA</gtr:id><gtr:title>Mutations in AQP5, encoding a water-channel protein, cause autosomal-dominant diffuse nonepidermolytic palmoplantar keratoderma.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a6cb0132e63f15da395f14e2f5217726"><gtr:id>a6cb0132e63f15da395f14e2f5217726</gtr:id><gtr:otherNames>Blaydon DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E5770A24-6FD6-44C8-8D61-4772A44FFCC5"><gtr:id>E5770A24-6FD6-44C8-8D61-4772A44FFCC5</gtr:id><gtr:title>New and recurrent AAGAB mutations in punctate palmoplantar keratoderma.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/afe935ed2ec68ab227617ddae225d59b"><gtr:id>afe935ed2ec68ab227617ddae225d59b</gtr:id><gtr:otherNames>Pohler E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3CF75D64-BCF0-427F-A22A-702E691A0D28"><gtr:id>3CF75D64-BCF0-427F-A22A-702E691A0D28</gtr:id><gtr:title>Old King coal - molecular mechanisms underlying an ancient treatment for atopic eczema.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1a06ac4c15fa5ab9d9f15bd95c259659"><gtr:id>1a06ac4c15fa5ab9d9f15bd95c259659</gtr:id><gtr:otherNames>McLean WH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0B758AAE-CD00-4D1B-84C6-9FC71E3C66DF"><gtr:id>0B758AAE-CD00-4D1B-84C6-9FC71E3C66DF</gtr:id><gtr:title>Achieving successful delivery of nucleic acids to skin: 6th Annual Meeting of the International Pachyonychia Congenita Consortium.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/08106e20b29c075afbbad3226ae231ed"><gtr:id>08106e20b29c075afbbad3226ae231ed</gtr:id><gtr:otherNames>Kaspar RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6E72717E-4200-4BAB-A35D-6343BECFB39F"><gtr:id>6E72717E-4200-4BAB-A35D-6343BECFB39F</gtr:id><gtr:title>Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/419292773106cb0a7c18e5615a7947ec"><gtr:id>419292773106cb0a7c18e5615a7947ec</gtr:id><gtr:otherNames>Samuelov L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1B793655-2291-42E1-9360-085840E1C09B"><gtr:id>1B793655-2291-42E1-9360-085840E1C09B</gtr:id><gtr:title>Tmem79/Matt is the matted mouse gene and is a predisposing gene for atopic dermatitis in human subjects.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f05f075d4358c2d78b4fd9bd1b68a270"><gtr:id>f05f075d4358c2d78b4fd9bd1b68a270</gtr:id><gtr:otherNames>Saunders SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1919B72B-7820-4612-95B7-4077002B8101"><gtr:id>1919B72B-7820-4612-95B7-4077002B8101</gtr:id><gtr:title>Pachyonychia congenita patients with mutations in KRT6A have more extensive disease compared with patients who have mutations in KRT16.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/295b4174b3be6efaa8ef6f5395c1e78e"><gtr:id>295b4174b3be6efaa8ef6f5395c1e78e</gtr:id><gtr:otherNames>Spaunhurst KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/54360D1B-E26C-4489-9534-6F2FF80F55E0"><gtr:id>54360D1B-E26C-4489-9534-6F2FF80F55E0</gtr:id><gtr:title>Large Intragenic Deletion in DSTYK Underlies Autosomal-Recessive Complicated Spastic Paraparesis, SPG23.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/21f6a74a058e015d4e6791267279c0be"><gtr:id>21f6a74a058e015d4e6791267279c0be</gtr:id><gtr:otherNames>Lee JY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/65DCC9CF-4F09-4BC9-9BDA-8B24F5745290"><gtr:id>65DCC9CF-4F09-4BC9-9BDA-8B24F5745290</gtr:id><gtr:title>Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita.</gtr:title><gtr:parentPublicationTitle>Journal of dermatological science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/33c495952b4fc5fe6774d1b49df82ab2"><gtr:id>33c495952b4fc5fe6774d1b49df82ab2</gtr:id><gtr:otherNames>Leachman SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0923-1811</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F02B3919-CFC0-4363-9393-43B5C5AF6EB9"><gtr:id>F02B3919-CFC0-4363-9393-43B5C5AF6EB9</gtr:id><gtr:title>Haploinsufficiency for AAGAB causes clinically heterogeneous forms of punctate palmoplantar keratoderma.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/afe935ed2ec68ab227617ddae225d59b"><gtr:id>afe935ed2ec68ab227617ddae225d59b</gtr:id><gtr:otherNames>Pohler E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/324854A2-371F-4195-BBF6-0C90967A49D5"><gtr:id>324854A2-371F-4195-BBF6-0C90967A49D5</gtr:id><gtr:title>Recessive mutations in the gene encoding frizzled 6 cause twenty nail dystrophy--expanding the differential diagnosis for pachyonychia congenita.</gtr:title><gtr:parentPublicationTitle>Journal of dermatological science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ee30dd370782ce25fab3dc90f4cebcf9"><gtr:id>ee30dd370782ce25fab3dc90f4cebcf9</gtr:id><gtr:otherNames>Wilson NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0923-1811</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/59E00259-CB2E-4DBF-8307-8D1ED7FC0A6C"><gtr:id>59E00259-CB2E-4DBF-8307-8D1ED7FC0A6C</gtr:id><gtr:title>Genotype-phenotype correlations among pachyonychia congenita patients with K16 mutations.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e0b724864d8662282599ac1a61ce0048"><gtr:id>e0b724864d8662282599ac1a61ce0048</gtr:id><gtr:otherNames>Fu T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/87FFB4C4-5006-489B-B9FC-D0C991165EED"><gtr:id>87FFB4C4-5006-489B-B9FC-D0C991165EED</gtr:id><gtr:title>Development of allele-specific gene-silencing siRNAs for TGFBI Arg124Cys in lattice corneal dystrophy type I.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6f942453d6b751e05bcbf8b025afdc00"><gtr:id>6f942453d6b751e05bcbf8b025afdc00</gtr:id><gtr:otherNames>Courtney DG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/932326F0-C6D5-495D-B41F-EE7FD7ED7FB1"><gtr:id>932326F0-C6D5-495D-B41F-EE7FD7ED7FB1</gtr:id><gtr:title>The molecular genetic analysis of the expanding pachyonychia congenita case collection.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ee30dd370782ce25fab3dc90f4cebcf9"><gtr:id>ee30dd370782ce25fab3dc90f4cebcf9</gtr:id><gtr:otherNames>Wilson NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9DAA0621-B217-4DE2-851E-9B313953850B"><gtr:id>9DAA0621-B217-4DE2-851E-9B313953850B</gtr:id><gtr:title>Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ea922bc4db1d3ac9a99cc64f7d1d0eea"><gtr:id>ea922bc4db1d3ac9a99cc64f7d1d0eea</gtr:id><gtr:otherNames>Paternoster L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F35C22C4-0128-4C42-9EE1-7B363BD832F9"><gtr:id>F35C22C4-0128-4C42-9EE1-7B363BD832F9</gtr:id><gtr:title>Development of allele-specific therapeutic siRNA for keratin 5 mutations in epidermolysis bullosa simplex.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/11fed8cbe5d1835e8044215728332a22"><gtr:id>11fed8cbe5d1835e8044215728332a22</gtr:id><gtr:otherNames>Atkinson SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E987C1A4-3E5D-466C-90AC-56DAD40165E1"><gtr:id>E987C1A4-3E5D-466C-90AC-56DAD40165E1</gtr:id><gtr:title>Punctate palmoplantar keratoderma type 1: a novel AAGAB mutation and efficacy of etretinate.</gtr:title><gtr:parentPublicationTitle>Acta dermato-venereologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2c53890064db5facaa5d83b374e28167"><gtr:id>2c53890064db5facaa5d83b374e28167</gtr:id><gtr:otherNames>Nomura T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0001-5555</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C9B19142-C0C1-420A-93A2-BA53F46DC4BC"><gtr:id>C9B19142-C0C1-420A-93A2-BA53F46DC4BC</gtr:id><gtr:title>Severe dermatitis, multiple allergies, and metabolic wasting syndrome caused by a novel mutation in the N-terminal plakin domain of desmoplakin.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/de448266df10355a46b2241955bd4724"><gtr:id>de448266df10355a46b2241955bd4724</gtr:id><gtr:otherNames>McAleer MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2D9312F0-0357-4F51-B18E-A7EE84B17A4C"><gtr:id>2D9312F0-0357-4F51-B18E-A7EE84B17A4C</gtr:id><gtr:title>CRISPR/Cas9 DNA cleavage at SNP-derived PAM enables both in vitro and in vivo KRT12 mutation-specific targeting.</gtr:title><gtr:parentPublicationTitle>Gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6f942453d6b751e05bcbf8b025afdc00"><gtr:id>6f942453d6b751e05bcbf8b025afdc00</gtr:id><gtr:otherNames>Courtney DG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0969-7128</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/81DA3E85-60D3-4800-BCA9-9046FB7DD149"><gtr:id>81DA3E85-60D3-4800-BCA9-9046FB7DD149</gtr:id><gtr:title>SiRNA-mediated selective inhibition of mutant keratin mRNAs responsible for the skin disorder pachyonychia congenita.</gtr:title><gtr:parentPublicationTitle>Annals of the New York Academy of Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bb2b3892d790bb4dcf1068f75965dad2"><gtr:id>bb2b3892d790bb4dcf1068f75965dad2</gtr:id><gtr:otherNames>Hickerson RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0077-8923</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9A734891-3F47-4EC8-ACF0-D5B4580A4233"><gtr:id>9A734891-3F47-4EC8-ACF0-D5B4580A4233</gtr:id><gtr:title>Transgrediens pachyonychia congenita (PC): case series of a nonclassical PC presentation.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1fa8ef0e8045ee05324b9c8e75169e76"><gtr:id>1fa8ef0e8045ee05324b9c8e75169e76</gtr:id><gtr:otherNames>Harris K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/68180C23-5BE7-4554-91E3-63E7F544C1CD"><gtr:id>68180C23-5BE7-4554-91E3-63E7F544C1CD</gtr:id><gtr:title>Germline Mutation in EXPH5 Implicates the Rab27B Effector Protein Slac2-b in Inherited Skin Fragility.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/09416e0d1555fa0eb3ebcac9402772c5"><gtr:id>09416e0d1555fa0eb3ebcac9402772c5</gtr:id><gtr:otherNames>McGrath JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1460A866-8B2C-4EDD-A65F-E6EC988F4EC6"><gtr:id>1460A866-8B2C-4EDD-A65F-E6EC988F4EC6</gtr:id><gtr:title>Paternal germ cell mosaicism in autosomal dominant pachyonychia congenita.</gtr:title><gtr:parentPublicationTitle>Archives of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d3b28deeaa76d15efb0d5aee60af28e5"><gtr:id>d3b28deeaa76d15efb0d5aee60af28e5</gtr:id><gtr:otherNames>Pho LN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-987X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9ED9BCBD-E824-46CD-9CD4-B7AAABE93043"><gtr:id>9ED9BCBD-E824-46CD-9CD4-B7AAABE93043</gtr:id><gtr:title>Loss-of-Function Mutations in the Gene Encoding Filaggrin Are Not Strongly Associated with Chronic Actinic Dermatitis.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b3af0d00c2093a21f07c697e3a07bb8a"><gtr:id>b3af0d00c2093a21f07c697e3a07bb8a</gtr:id><gtr:otherNames>Harkins CP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/59BFE86F-AF89-4611-AC38-825A29B8AF4C"><gtr:id>59BFE86F-AF89-4611-AC38-825A29B8AF4C</gtr:id><gtr:title>Novel autosomal dominant mutation in loricrin presenting as prominent ichthyosis.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/afe935ed2ec68ab227617ddae225d59b"><gtr:id>afe935ed2ec68ab227617ddae225d59b</gtr:id><gtr:otherNames>Pohler E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/88514DAB-EDE0-402D-BDAB-C86C7ACA40E5"><gtr:id>88514DAB-EDE0-402D-BDAB-C86C7ACA40E5</gtr:id><gtr:title>Allele-specific siRNA silencing for the common keratin 12 founder mutation in Meesmann epithelial corneal dystrophy.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9c89a5fb166c140e6fb30bd0d146c474"><gtr:id>9c89a5fb166c140e6fb30bd0d146c474</gtr:id><gtr:otherNames>Allen EH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CE407011-CEB1-41C0-81A4-B292566A4AB2"><gtr:id>CE407011-CEB1-41C0-81A4-B292566A4AB2</gtr:id><gtr:title>Development of allele-specific therapeutic siRNA in Meesmann epithelial corneal dystrophy.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7d59f85b8e3d5471bf73b246942c201b"><gtr:id>7d59f85b8e3d5471bf73b246942c201b</gtr:id><gtr:otherNames>Liao H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/65C20518-EEEC-4917-9888-218834C60BC6"><gtr:id>65C20518-EEEC-4917-9888-218834C60BC6</gtr:id><gtr:title>Genome-wide comparative analysis of atopic dermatitis and psoriasis gives insight into opposing genetic mechanisms.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d0ccf974f83ca48e2ea50acd96b3f211"><gtr:id>d0ccf974f83ca48e2ea50acd96b3f211</gtr:id><gtr:otherNames>Baurecht H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0802780</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>A9061818-9B1E-495A-9617-7C77200827C2</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Eye</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>7EE9741E-CF94-420A-B0AB-A7811523CF2C</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Skin</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>